NIKKEI 225
38,617.62 -15.40 (-0.04%) HANG SENG
18,055.69 -279.63 (-1.52%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.40 +9.40 (+0.40%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
51,018.82 -688.01 (-1.33%)
APLS Jun 2024 30.000 call
| Previous close | 13.50 |
| Open | 13.26 |
| Bid | 12.20 |
| Ask | 13.10 |
| Strike | 30.00 |
| Expiry date | 2024-06-21 |
| Day's range | 13.26 - 13.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 605 |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
